Cargando…
The potential for one drug, administered at the earliest preclinical stage, to prevent the subsequent decline of cognition that eventuates in dementia
In the process that eventuates in mild cognitive impairment (MCI) and ultimately in Alzheimer's dementia, the earliest identifiable change is in the function of synapses. If started at that early point in time, when there is subjective but not objective memory loss plus abnormal brain imaging w...
Autor principal: | Fessel, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528321/ https://www.ncbi.nlm.nih.gov/pubmed/33024811 http://dx.doi.org/10.1002/trc2.12084 |
Ejemplares similares
-
A vaccine to prevent initial loss of cognition and eventual Alzheimer's disease in elderly persons
por: Fessel, Jeffrey
Publicado: (2021) -
Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs
por: Fessel, Jeffrey
Publicado: (2019) -
Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types
por: Fessel, Jeffrey
Publicado: (2023) -
Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022) -
Analysis of Why Alzheimer’s Dementia Never Spontaneously Reverses, Suggests the Basis for Curative Treatment
por: Fessel, Jeffrey
Publicado: (2023)